Your browser doesn't support javascript.
loading
Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma.
Zhang, Qiming; He, Yao; Luo, Nan; Patel, Shashank J; Han, Yanjie; Gao, Ranran; Modak, Madhura; Carotta, Sebastian; Haslinger, Christian; Kind, David; Peet, Gregory W; Zhong, Guojie; Lu, Shuangjia; Zhu, Weihua; Mao, Yilei; Xiao, Mengmeng; Bergmann, Michael; Hu, Xueda; Kerkar, Sid P; Vogt, Anne B; Pflanz, Stefan; Liu, Kang; Peng, Jirun; Ren, Xianwen; Zhang, Zemin.
Affiliation
  • Zhang Q; BIOPIC, Beijing Advanced Innovation Center for Genomics, School of Life Sciences, Peking University, Beijing 100871, China.
  • He Y; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China.
  • Luo N; Department of Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China; Ninth School of Clinical Medicine, Peking University, Beijing 100038, China.
  • Patel SJ; Department of Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA.
  • Han Y; BIOPIC, Beijing Advanced Innovation Center for Genomics, School of Life Sciences, Peking University, Beijing 100871, China.
  • Gao R; BIOPIC, Beijing Advanced Innovation Center for Genomics, School of Life Sciences, Peking University, Beijing 100871, China.
  • Modak M; Department of Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharma, Birkendorfer Str. 65, 88400 Biberach, Germany.
  • Carotta S; Department of Cancer Cell Signaling, Boehringer Ingelheim RCV GmBH & Co KG., Dr. Boehringer Gasse 5-11, 1120 Vienna, Austria.
  • Haslinger C; Department of Computational Biology and Genomics, Boehringer Ingelheim Pharma, Birkendorfer Str. 65, 88400 Biberach, Germany.
  • Kind D; Department of Computational Biology and Genomics, Boehringer Ingelheim Pharma, Birkendorfer Str. 65, 88400 Biberach, Germany.
  • Peet GW; Department of Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA.
  • Zhong G; BIOPIC, Beijing Advanced Innovation Center for Genomics, School of Life Sciences, Peking University, Beijing 100871, China.
  • Lu S; BIOPIC, Beijing Advanced Innovation Center for Genomics, School of Life Sciences, Peking University, Beijing 100871, China.
  • Zhu W; Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing 100044, China.
  • Mao Y; Department of Liver Surgery, Peking Union Medical College Hospital, Beijing 100730, China.
  • Xiao M; Department of Retroperitoneal Tumor Surgery, Peking University International Hospital, Beijing 102206, China.
  • Bergmann M; Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Hu X; BIOPIC, Beijing Advanced Innovation Center for Genomics, School of Life Sciences, Peking University, Beijing 100871, China.
  • Kerkar SP; Department of Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA.
  • Vogt AB; Department of Human Cancer Immunology, Boehringer Ingelheim RCV GmBH & Co KG., Dr. Boehringer Gasse 5-11, 1120 Vienna, Austria.
  • Pflanz S; Department of Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharma, Birkendorfer Str. 65, 88400 Biberach, Germany.
  • Liu K; Department of Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA. Electronic address: kang_3.liu@boehringer-ingelheim.com.
  • Peng J; Department of Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China; Ninth School of Clinical Medicine, Peking University, Beijing 100038, China. Electronic address: pengjr@medmail.com.cn.
  • Ren X; BIOPIC, Beijing Advanced Innovation Center for Genomics, School of Life Sciences, Peking University, Beijing 100871, China. Electronic address: renxwise@pku.edu.cn.
  • Zhang Z; BIOPIC, Beijing Advanced Innovation Center for Genomics, School of Life Sciences, Peking University, Beijing 100871, China; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China. Electronic address: zemin@pku.edu.cn.
Cell ; 179(4): 829-845.e20, 2019 Oct 31.
Article in En | MEDLINE | ID: mdl-31675496
The immune microenvironment of hepatocellular carcinoma (HCC) is poorly characterized. Combining two single-cell RNA sequencing technologies, we produced transcriptomes of CD45+ immune cells for HCC patients from five immune-relevant sites: tumor, adjacent liver, hepatic lymph node (LN), blood, and ascites. A cluster of LAMP3+ dendritic cells (DCs) appeared to be the mature form of conventional DCs and possessed the potential to migrate from tumors to LNs. LAMP3+ DCs also expressed diverse immune-relevant ligands and exhibited potential to regulate multiple subtypes of lymphocytes. Of the macrophages in tumors that exhibited distinct transcriptional states, tumor-associated macrophages (TAMs) were associated with poor prognosis, and we established the inflammatory role of SLC40A1 and GPNMB in these cells. Further, myeloid and lymphoid cells in ascites were predominantly linked to tumor and blood origins, respectively. The dynamic properties of diverse CD45+ cell types revealed by this study add new dimensions to the immune landscape of HCC.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Membrane Glycoproteins / Carcinoma, Hepatocellular / Cation Transport Proteins / Inflammation / Liver Neoplasms Language: En Journal: Cell Year: 2019 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Membrane Glycoproteins / Carcinoma, Hepatocellular / Cation Transport Proteins / Inflammation / Liver Neoplasms Language: En Journal: Cell Year: 2019 Document type: Article Affiliation country: Country of publication: